

ValleyHealth
Shenandoah
Memorial Hospital

August 2, 2007

U.S. Nuclear Regulatory Commission
Division of Nuclear Materials Safety
Region I
Attn: Licensing Assistance Team
475 Allendale Road
King of Prussia, PA 19406

03020154

Reference: NRC License No. 45-11519-02
Notification of Selection of Authorized Users Under 10CFR35.14

Dear Sir or Madam:

We recently reviewed and approved the following authorized users for uses identified in 10 CFR 35.200:


Edward Bonyak, M.D.
Jason T. Call, M.D.
Frederic T. Farra, M.D.
John C. Hardy, M.D.
Trisha B. Nashed, M.D.
Philip J. O'Donnell, M.D.
Juan Pittaluga, M.D.
Daniel Reese, M.D.
Jeffrey Skiles, M.D.
Ajay Virmani, M.D.
James Dixon Brown, M.D.

RECEIVED
REGION 1
2007 AUG 16 AM 10:38

These authorized users are presently licensed under NRC License no 45-01589-01, and a copy of this license is attached. This is to provide notification of our action.

Should there be any questions, please contact Roy F. Heltzel, Jr., our consulting physicist, at 757-410-9051.

Very truly yours,



Floyd Heater
President, Chief Executive Officer

140944

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES

Amendment No. 89

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Valley Health System 2. P. O. Box 3340 1840 Amherst Street Winchester, Virginia 22604-2540		In accordance with the letter dated October 3, 2005, 3. License number 45-01589-01 is amended in its entirety to read as follows: <hr/> 4. Expiration date March 31, 2014 <hr/> 5. Docket No. 030-03308 Reference No.	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1000 millicuries	
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed source (AEA Technology Model CDC T1 and 3M Health Physics Service Model 6500 Series)	D. 1200 millicuries	
E. Depleted Uranium	E. Cadmium plated metal	E. 106 kilograms	
F. Yttrium 90	F. Any	F. 110 millicuries	
G. Iodine 125	G. Liquid Iotrex as part of the GliaSite RTS System	G. 8 curies	

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Shielding in a linear accelerator.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

MATERIALS LICENSE SUPPLEMENTARY SHEET

 License Number
45-01589-01

 Docket or Reference Number
030-03308

Amendment No. 89

F. For calibration of instruments.

G. For brachytherapy use in the Proxima Therapeutics' GliaSite Radiotherapy system.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at Winchester Medical Center, 1840 Amherst Street, Winchester, Virginia and Shenandoah Valley Cancer Center, 1870 Amherst Street, Winchester, Virginia.
11. The Radiation Safety Officer for this license is Dana Hare, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Norman J. Smith, M.D.	35.400; Iodine 125 for use in the GliaSite RTS System
Margaret Toxopeus, M.D.	35.100; 35.200; 35.300; 35.400
John L. Wood, M.D.	35.100; 35.200; 35.300
Frederic T. Farra, M.D.	35.200
James Dixon Brown, M.D.	35.200
Philip J. O'Donnell, M.D.	35.200
David Kent Harry, M.D.	35.100; 35.200
Karen Straus, M.D.	Iodine 125 for use in the GliaSite RTS System
Francis W. Willi, M.D.	35.100; 35.200
Blake Howard Watts, M.D.	35.100; 35.200; 35.300
Robert J. Foust, M.D.	35.100; 35.200
Bruce L. Flax, M.D.	35.400; Iodine 125 for use in the GliaSite RTS System
Ronald G. Repasky, M.D.	35.100; 35.200

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-01589-01Docket or Reference Number
030-03308

Amendment No. 89

<u>Authorized Users</u>	<u>Material and Use</u>
Ajay Virmani, M.D.	35.200
David Snow, M.D.	35.100; 35.200
John C. Hardy, M.D.	35.200
Joseph W. Poe, M.D.	35.100; 35.200; 35.300
David E. Magarik, M.D.	35.100; 35.200
Curtis J. Thwing, M.D.	35.100; 35.200; 35.300
Edward Bonyak, M.D.	35.200
Trisha B. Nashed, M.D.	35.200
Kyle Wilson Young, M.D.	35.100; 35.200
Preston Stuart Fox, M.D.	35.100; 35.200
Dorthe Sophie Brandt, M.D.	35.100; 35.200
Jason T. Cail, M.D.	35.100; 35.200
Juan Pittaluga, M.D.	35.200
Daniel Reese, M.D.	35.200
Jeffrey Skiles, M.D.	35.200
Richard Rizzo, M.D.	35.100; 35.200
Anca Iliescu, M.D.	35.200

C. The following individuals are authorized users for non-medical uses as indicated:

<u>Users</u>	<u>Material and Use</u>
Dana Hare, M.S.	Depleted Uranium shielding in a linear accelerator, Yttrium 90 for calibration of instruments
Maurice R. Keeler	Depleted Uranium shielding in a linear accelerator, Yttrium 90 for calibration of instruments.

NRC FORM 74A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

45-01589-01

Docket or Reference Number

030-03308

Amendment No. 89

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated October 22, 2003 (ML032970404)
B. Letter dated April 26, 2004 (ML041240112)

For the U.S. Nuclear Regulatory Commission

Date December 19, 2005

By

Original signed by Tara L. Weidner

Tara L. Weidner

Medical Branch

Division of Nuclear Materials Safety

Region I

King of Prussia, Pennsylvania 19406

Monday, December 19, 2005 3:57:42 PM

This is to acknowledge the receipt of your letter/application dated

8/2/2007, and to inform you that the initial processing which includes an administrative review has been performed.

☒ AMEND. 45-11519-02
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 140944.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.